ClinicalTrials HQ

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting · NCT03909334 · Registry updated 2026-04-17
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, metastatic malignant neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 22026-04-17NCT03909334

3 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Eli Lilly and Company370
M.D. Anderson Cancer Center1145
Xiuning Le1

12 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Columbia University Irving Medical CenterNew YorkUnited States234
Fred Hutchinson Cancer Research CenterSeattleUnited States71
Georgetown UniversityWashington D.C.United States21
Indiana Univesity Melvin and Bren Simon Cancer CenterIndianapolisUnited States1
MD Anderson Cancer CenterHoustonUnited States589
Moffitt Cancer CenterTampaUnited States523
New York University Cancer CenterNew YorkUnited States1
Northwestern University Feinberg School Of MedicineChicagoUnited States49
Providence Portland Medical CenterPortlandUnited States324
Rush University Medical CenterChicagoUnited States283
Summit Medical Group, PABerkeley HeightsUnited States1
University of Virginia Health SystemCharlottesvilleUnited States57